Download Biosimilars and interchangeable biologics: strategic by Sarfaraz K. Niazi PDF

By Sarfaraz K. Niazi

What’s the take care of Biosimilars?

Biosimilars are gaining momentum as new protein healing applicants which could aid fill an essential desire within the healthcare undefined. The organic medications are produced via recombinant DNA expertise that enables for large-scale construction and an total aid time in expenditures and improvement.

Part of a two-volume set that covers various points of biosimilars, Biosimilars and Interchangeable Biologics: Strategic components explores the strategic making plans aspect of biosimilar medicines and ambitions concerns surrounding biosimilars which are associated with criminal concerns. This contains significant patents and highbrow estate, regulatory pathways, and issues approximately affordability on an international scale. It addresses the complexity of biosimilar items, and it discusses the usage of biosimilars and comparable organic medications in increasing international markets.

Of particular curiosity to practitioners, researchers, and scientists within the biopharmaceutical undefined, this quantity examines the technology, expertise, finance, legality, ethics, and politics of biosimilar medicinal drugs. It considers strategic making plans components that come with an total knowing of the background and the present prestige of the artwork and technological know-how of biosimilars, and it offers distinct descriptions of the criminal, regulatory, and advertisement features. The e-book additionally provides a world technique on tips on how to construct, take to industry, and deal with the subsequent iteration of biosimilars all through their existence cycle.

Show description

Read or Download Biosimilars and interchangeable biologics: strategic elements PDF

Best biotechnology books

Capitalizing on New Needs and New Opportunities: Government - Industry Partnerships in Biotechnology and Information Technologies (Compass Series (Washington, D.C.).)

This record addresses a subject matter of well-known coverage drawback. To catch the advantages of large U. S. investments in biomedical R&D, parallel investments in quite a lot of possible unrelated disciplines also are required. This document summarizes a tremendous convention that reviewed our nation's R&D help for biotechnology and data applied sciences.

Biosensors - A Practical Approach

Over the last two decades, the sphere of biosensor examine have had an important effect in either laboratory learn and the economic region. Over that interval, biosensors have revolutionised the care and administration of diabetes and feature had very important affects in different different components of scientific diagnostics.

The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions

Within the fall of 2010, the U. S. nationwide Academies (consisting of the nationwide Academy of Sciences, the nationwide Academy of Engineering, and the Institute of drugs) and the Russian Academy of Sciences (in cooperation with the Russian Academy of scientific Sciences and the Russian Academy of Agricultural Sciences) initiated a joint learn of U.

Downstream Industrial Biotechnology: Recovery and Purification

A reasonable, simply obtainable table reference on biomanufacturing, serious about downstream restoration and purificationAdvances within the basic wisdom surrounding biotechnology, novel fabrics, and complex engineering techniques stay translated into bioprocesses that carry new items to marketplace at a considerably speedier speed than so much different industries.

Additional info for Biosimilars and interchangeable biologics: strategic elements

Sample text

Cloning of a specific gene in the laboratory or the construction of a synthetic gene 2. Insertion into a host cell and subcloning in a microorganism or cell culture 3. Large-scale fermentation or cell culture processes 5. Purification of the macromolecular proteins 6. Animal testing, clinical testing, regulatory approval, and marketing This applies to both rDNA-derived products as well as monoclonal antibody products. Biotechnology-derived products are therefore readily differentiated from proteins or peptides that have been obtained by isolation from natural source materials such as plasma, serum, or tissue, or by chemical synthesis even though the nature of the product is same and even labeled as such, for example, rhEPO (recombinant human erythropoietin) or rhIFN (recombinant human interferon); except for the undesirable changes that may arise as a result of processing, these products are indeed exact replica of what the body produces.

This chapter provides an extensive study of these guidelines, relative comparisons of the various entry points, and suggests the changes about to become worldwide in the regulatory landscape of biosimilars. S. commercialization There is no doubt that commercialization of biosimilars in the United States will take a hybrid path, somewhere between generic and branded products. The challenges in creating a pathway for distribution of these products are discussed, along with a pricing structure and satisfying stakeholder needs.

The same holds true for cytokines like pegylated filgrastim and most anticancer drugs. The cost of biological drugs used in the treatment of cancer can run much higher. The high cost of these drugs is justified by the originators based on the complexity and difficulties of their manufacture and a much lower success rate in new discoveries. However, it is abundantly clear now that the price of these drugs is driven mainly by economic incentives supported by complex intellectual property laws that have allowed some of these drugs to have an exclusivity of over 30 years, such as interferon alpha, etanercept, and several others.

Download PDF sample

Rated 4.68 of 5 – based on 28 votes